Real-World study tests fruquintinib for Tough-to-Treat colorectal cancer

NCT ID NCT06787105

Recruiting now Disease control Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is observing how well the drug fruquintinib works for people with metastatic colorectal cancer who have already tried standard treatments. About 150 participants in Germany will be treated as part of their normal care, and researchers will track tumor response, survival, side effects, and quality of life. The goal is to see if fruquintinib helps control the disease in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fruquintinib
What this could lead to: If successful, this study could confirm that fruquintinib works well in everyday clinical practice for patients with advanced colorectal cancer who have run out of other options.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to 150 patients in Germany, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (MCRC)

Contacts and locations

Show contact details

Locations

Onkologische Schwerpunktpraxis
RECRUITING

Hanover, Lower Saxony, 30161, Germany

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.